Nano-loaded human umbilical cord mesenchymal stem cells as targeted carriers of doxorubicin for breast cancer therapy

References

• Jemal A, Bray F, Center MM, et al. Global cancer statistics. Ca Cancer J Clin. 2011;61:69–90.
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303:1818–1822.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res. 2007;24:1–16.
   PubMed Web of Science ®Google Scholar
• Cukierman E, Khan DR. The benefits and challenges associated with the use of drug delivery systems in cancer therapy. Biochem Pharmacol. 2010;80:762–770.
   PubMed Web of Science ®Google Scholar
• Kose K, Denizli A. Poly(hydroxyethyl methacrylate) based magnetic nanoparticles for lysozyme purification from chicken egg white. Artif Cells Nanomed Biotechnol.2013;41:13–20.
   PubMed Web of Science ®Google Scholar
• He YJ, Xing L, Cui PF, et al. Transferrin-inspired vehicles based on pH-responsive coordination bond to combat multidrug-resistant breast cancer. Biomaterials. 2017;113:266–278.
   PubMed Web of Science ®Google Scholar
• Porada CD, Almeida-Porada G. Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery. Adv Drug Deliv Rev. 2010;62:1156–1166.
   PubMed Web of Science ®Google Scholar
• Shah K. Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev. 2012;64:739–748.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Ito Y, Kawano Y, et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther. 2004;11:1155–1164.
   PubMed Web of Science ®Google Scholar
• Gao P, Ding Q, Wu Z, et al. Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. Cancer Lett. 2010;290:157–166.
   PubMed Web of Science ®Google Scholar
• Ling X, Marini F, Konopleva M, et al. Mesenchymal stem cells overexpressing IFN-beta inhibit breast cancer growth and metastases through Stat3 signaling in a syngeneic tumor model. Cancer Microenviron. 2010;3:83–95.
   PubMedGoogle Scholar
• Aboody KS, Najbauer J, Metz MZ, et al. Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies. Science Transl Med. 2013;5:184ra159.
   Web of Science ®Google Scholar
• Pessina A, Piccirillo M, Mineo E, et al. Role of SR-4987 stromal cells in the modulation of doxorubicin toxicity to in vitro granulocyte-macrophage progenitors (CFU-GM). Life Sci. 1999;65:513–523.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Tang S, Guo J, et al. Targeted delivery of doxorubicin by nano-loaded mesenchymal stem cells for lung melanoma metastases therapy. Sci Rep. 2017;7:44758.
   PubMed Web of Science ®Google Scholar
• Pessina A, Bonomi A, Cocce V, et al. Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy. PloS One. 2011;6:e28321.
   PubMed Web of Science ®Google Scholar
• Sasportas LS, Kasmieh R, Wakimoto H, et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA. 2009;106:4822–4827.
   PubMed Web of Science ®Google Scholar
• Li L, Huang X, Liu T, et al. Overcoming multidrug resistance with mesoporous silica nanorods as nanocarrier of doxorubicin. J Nanosci Nanotech. 2012;12:4458–4466.
   PubMed Web of Science ®Google Scholar
• Chithrani BD, Ghazani AA, Chan WC. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 2006;6:662–668.
   PubMed Web of Science ®Google Scholar
• Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–147.
   PubMed Web of Science ®Google Scholar
• Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 2006;8:315–317.
   PubMed Web of Science ®Google Scholar
• Xue J, Zhao Z, Zhang L, et al. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nature Nanotech. 2017;12:692–700.
   PubMed Web of Science ®Google Scholar
• Anari E, Akbarzadeh A, Zarghami N. Chrysin-loaded PLGA-PEG nanoparticles designed for enhanced effect on the breast cancer cell line. Artif Cells Nanomed Biotechnol. 2016;44:1410–1416.
   PubMed Web of Science ®Google Scholar
• Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004;56:1649–1659.
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751–760.
   PubMed Web of Science ®Google Scholar
• Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nature reviews. J Clin Oncol. 2010;7:653–664.
   Google Scholar
• Herizchi R, Abbasi E, Milani M, et al. Current methods for synthesis of gold nanoparticles. Artif Cells Nanomed Biotechnol. 2016;44:596–602.
   PubMed Web of Science ®Google Scholar
• Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63:131–135.
   PubMed Web of Science ®Google Scholar
• Niu M, Naguib YW, Aldayel AM, et al. Biodistribution and in vivo activities of tumor-associated macrophage-targeting nanoparticles incorporated with doxorubicin. Mol Pharmaceutics. 2014;11:4425–4436.
   PubMed Web of Science ®Google Scholar
• Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nature reviews. Cancer. 2006;6:583–592.
   PubMed Web of Science ®Google Scholar
• Huang X, Peng X, Wang Y, et al. A reexamination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands. ACS Nano. 2010;4:5887–5896.
   PubMed Web of Science ®Google Scholar
• Gao Z, Zhang L, Hu J, et al. Mesenchymal stem cells: a potential targeted-delivery vehicle for anti-cancer drug, loaded nanoparticles. Nanomedicine. 2013;9:174–184.
   PubMed Web of Science ®Google Scholar
• Park JS, Suryaprakash S, Lao YH, et al. Engineering mesenchymal stem cells for regenerative medicine and drug delivery. Methods. 2015;84:3–16.
   PubMed Web of Science ®Google Scholar
• Ackova DG, Kanjevac T, Rimondini L, et al. Perspectives in engineered mesenchymal stem/stromal cells based anti-cancer drug delivery systems. Recent Pat Anticancer Drug Discov. 2016;11:98–111.
   PubMed Web of Science ®Google Scholar
• Armulik A. Splice variants of human beta 1 integrins: origin, biosynthesis and functions. Front Biosci. 2002;7:d219–d227.
   PubMed Web of Science ®Google Scholar
• Ebrahim EK, Assem MM, Amin AI, et al. FLT3 internal tandem duplication mutation, cMPL and CD34 expressions predict low survival in acute myeloid leukemia patients. Ann Clin Lab Sci. 2016;46:592–600.
   PubMed Web of Science ®Google Scholar
• Hansen KR, Resta R, Webb CF, et al. Isolation and characterization of the promoter of the human 5'-nucleotidase (CD73)-encoding gene. Gene. 1995;167:307–312.
   PubMed Web of Science ®Google Scholar
• Ince S, Kutsch M, Shydlovskyi S, et al. The human guanylate-binding proteins hGBP-1 and hGBP-5 cycle between monomers and dimers only. Febs J. 2017;284:2284–2301.
   PubMed Web of Science ®Google Scholar
• Jacobsen M, Schweer D, Ziegler A, et al. A point mutation in PTPRC is associated with the development of multiple sclerosis. Nat Genet. 2000;26:495–499.
   PubMed Web of Science ®Google Scholar
• Leyton L, Hagood JS. Thy-1 modulates neurological cell-cell and cell-matrix interactions through multiple molecular interactions. Adv Neurol. 2014;8:3–20.
   Google Scholar
• Stalhammar ME, Sindelar R, Douhan HL. Neutrophil receptor response to bacterial N-formyl peptides is similar in term newborn infants and adults in contrast to IL-8. Scand J Immunol. 2016;84:332–337.
   PubMed Web of Science ®Google Scholar